Avellino Lab USA, an operator of a biotech company intended to leverage genetic data, agreed to go public via a SPAC merger with Senior Connect Acquisition I. Financial terms were not disclosed. The primary driver of its business is the aggregation, curation, and deep analysis of vast amounts of genetic data to provide solutions for early detection of disease states in the areas of ophthalmology, oncology and infectious disease. Avellino's business has a strong track record of diagnosing genetic conditions, initially focused on corneal dystrophies and other inherited diseases in ophthalmology.